Program Faculty


The Division of Pediatric Hematology/Oncology has undergone a period of marked growth over the past 5 years. The enhanced program improves the care and quality of life of children being treated for cancer and blood disorders, expanded our research efforts, and allowed us to develop a Fellowship Training Program. This growth has included recruitment of new faculty, the development of a bone marrow transplant program, enhanced programs in neuro-oncology, sickle cell disease, hemostasis/thrombosis and basic science research efforts.

Barbara Miller, M.D. is a Professor of Pediatrics and Biochemistry and Molecular Biology at the Pennsylvania State University College of Medicine and Division Chief of Pediatric Hematology/Oncology. She is the Vice Chairman for Research in the Department of Pediatrics and holds the Christopher Millard Endowed Chair in Pediatric Oncology Research. She has an NIH-funded research program in her laboratory dedicated to understanding the role of the TRP  channel family in erythropoiesis. Her laboratory is also studying the roles of other TRP channels in tumorigenesis and chemotherapy resistance.

Moshe Bell, M.D. is an Associate Professor in the Division of Pediatrics. He has an interest in Fellow Education and Experimental Therapeutics. He is the Director of Pediatric Hematology/Oncology Outpatient Services.

George Blackall, Psy.D., MBA is a Pediatric Psychologist and Professor of Pediatrics, Humanities and Psychiatry at the Penn State University College of Medicine. In addition to patient care, he serves as the Vice Chair of the Ethics Committee and teaches Ethics to medical students.

Melanie Comito, M.D. is an Associate Professor of Pediatrics and is the Education Director for the Division of Pediatric Hematology/Oncology.  In this role, she is the Program Director for the Pediatric Hematology/Oncology Fellowship Program and has played a major role in the mentoring of fellows and residents.She is the Director of the Pediatric Neuro-Oncology program and her research interests are in improving the survival of infants and young children with malignant brain tumors by the development of more effective therapies with fewer and less severe side effects.Other research interests include the study of survivor-ship issues for patients with brain tumors and other childhood cancers.  

Sinisa Dovat, MD, Ph.D. was recruited in 2010 from the University of Wisconsin in Madison. He serves as the Four Diamond Endowed Chair and the Director of Translational Research and Experimental Therapeutics. He has an active NIH-funded laboratory that is dedicated to translational research in childhood cancer. The research projects Dr. Dovat is pursuing are: Regulation of Tumor Suppression in Childhood Leukemia; Accelerated Drug Discovery for Childhood Malignancies; and Epigenomic Control of Cellular Immortalization and Senescence. Two assistant professor-level scientists work in Dr. Dovat's laboratory to collaborate in these projects.

Mary Lynn Fecile, M.D., Ph.D. is an Assistant Professor of Pediatric Hematology/Oncology and the Director of the Sickle Cell Program.

Andrew Freiberg, M.D. is an Associate Professor in the Division and has a special interest in hematology and medical student education. He has run a number of industry-related trials in Hematology. He is actively involved in medical student education and organizes the divisional tumor board.   Robert Greiner, M.D. completed his pediatric hematology/oncology fellowship at Duke University Medical Center in 2009 before joining the division as an Assistant Professor of Pediatrics in July 2009. His main clinical interests are in the areas of sarcomas, neuro-oncology, leukemia, stem cell transplantation, and late effects of pediatric cancer therapy. He is a member of the division's pediatric neuro-oncology and stem cell transplant programs and is also the Director of the division's long-term follow-up program for survivors of pediatric cancer.

John Kuttesch, Jr., MD, Ph.D. joined Penn State Children's Hospital in September 2010. He is the Director of Clinical Research and Co-Director of the Four Diamonds Program in Experimental Therapeutics. His research interests include early phase clinical trial design and drug development of novel cancer therapeutics, with particular expertise in innovative therapeutic strategies for childhood brain tumors and solid tumors.

John Neely, M.D. is a professor of Pediatrics and has been with the program for over 20 years. He has a joint appointment in Family Medicine and has started a program in holistic care for cancer patients.